Alidornase alfa: Interim Ph II data

Interim data from an open-label, Israeli Phase II trial in 13 evaluable CF patients previously treated with Pulmozyme dornase alfa showed that once-daily 2.5 mg inhaled alidornase alfa for 28 days led...